Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/bph.15260
Keywords
abdominal aortic aneurysm; mouse models; pathology
Categories
Funding
- Queensland Government
- Study, Education and Research Trust Fund
- Townsville Hospital and Health Service
- National Health and Medical Research Council [1117601, 1062671, 1079369, 1098717]
- National Health and Medical Research Council of Australia [1062671, 1098717] Funding Source: NHMRC
Ask authors/readers for more resources
Abdominal aortic aneurysm (AAA) rupture is estimated to cause 200,000 deaths each year. Currently, the only treatment for AAA is surgical repair; however, this is only indicated for large asymptomatic, symptomatic or ruptured aneurysms, is not always durable, and is associated with a risk of serious perioperative complications. As a result, patients with small asymptomatic aneurysms or who are otherwise unfit for surgery are treated conservatively, but up to 70% of small aneurysms continue to grow, increasing the risk of rupture. There is thus an urgent need to develop drug therapies effective at slowing AAA growth. This review describes the commonly used mouse models for AAA. Recent research in these models highlights key roles for pathways involved in inflammation and cell turnover in AAA pathogenesis. There is also evidence for long non-coding RNAs and thrombosis in aneurysm pathology. Further well-designed research in clinically relevant models is expected to be translated into effective AAA drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available